Net Income (Loss) Attributable to Parent in USD of Galera Therapeutics, Inc. from Q1 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Galera Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2018 to Q3 2025.
  • Galera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$1,388,000.000, a 75.1% increase year-over-year.
  • Galera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$8,986,000.000, a 54.2% increase year-over-year.
  • Galera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$18,957,000.000, a 67.9% increase from 2023.
  • Galera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$59,082,000.000, a 5.05% increase from 2022.
  • Galera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$62,222,000.000, a 22.7% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Galera Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$8,986,000 -$1,388,000 +$4,193,000 +75.1% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$13,179,000 -$1,075,000 +$2,989,000 +73.5% 01 Apr 2025 30 Jun 2025 10-Q 13 Nov 2025
Q1 2025 -$16,168,000 -$1,592,000 +$2,789,000 +63.7% 01 Jan 2025 31 Mar 2025 10-Q 13 Nov 2025
Q4 2024 -$18,957,000 -$4,931,000 +$656,000 +11.7% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$19,613,000 -$5,581,000 +$9,492,000 +63% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$29,105,000 -$4,064,000 +$16,648,000 +80.4% 01 Apr 2024 30 Jun 2024 10-Q 13 Nov 2025
Q1 2024 -$45,753,000 -$4,381,000 +$13,329,000 +75.3% 01 Jan 2024 31 Mar 2024 10-Q 13 Nov 2025
Q4 2023 -$59,082,000 -$5,587,000 +$10,601,000 +65.5% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$69,683,000 -$15,073,000 +$960,000 +6% 01 Jul 2023 30 Sep 2023 10-Q 13 Dec 2024
Q2 2023 -$70,643,000 -$20,712,000 -$6,154,000 -42.3% 01 Apr 2023 30 Jun 2023 10-Q 13 Dec 2024
Q1 2023 -$64,489,000 -$17,710,000 -$2,267,000 -14.7% 01 Jan 2023 31 Mar 2023 10-Q 13 Dec 2024
Q4 2022 -$62,222,000 -$16,188,000 +$619,000 +3.7% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024
Q3 2022 -$62,841,000 -$16,033,000 +$6,593,000 +29.1% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$69,434,000 -$14,558,000 +$7,828,000 +35% 01 Apr 2022 30 Jun 2022 10-Q 14 Nov 2023
Q1 2022 -$77,262,000 -$15,443,000 +$3,272,000 +17.5% 01 Jan 2022 31 Mar 2022 10-Q 14 Nov 2023
Q4 2021 -$80,534,000 -$16,807,000 +$3,259,000 +16.2% 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023
Q3 2021 -$83,793,000 -$22,626,000 -$5,548,000 -32.5% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 -$78,245,000 -$22,386,000 -$3,729,000 -20% 01 Apr 2021 30 Jun 2021 10-Q 09 Nov 2022
Q1 2021 -$74,516,000 -$18,715,000 -$298,000 -1.6% 01 Jan 2021 31 Mar 2021 10-Q 09 Nov 2022
Q4 2020 -$74,218,000 -$20,066,000 -$3,394,000 -20.4% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022
Q3 2020 -$70,824,000 -$17,078,000 -$3,727,000 -27.9% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021
Q2 2020 -$67,097,000 -$18,657,000 -$7,099,000 -61.4% 01 Apr 2020 30 Jun 2020 10-Q 10 Nov 2021
Q1 2020 -$59,998,000 -$18,417,000 -$8,068,000 -78% 01 Jan 2020 31 Mar 2020 10-Q 10 Nov 2021
Q4 2019 -$51,930,000 -$16,672,000 -$8,109,000 -94.7% 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021
Q3 2019 -$43,821,000 -$13,351,000 -$8,102,000 -1.5% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$35,719,000 -$11,558,000 -$7,227,000 -1.7% 01 Apr 2019 30 Jun 2019 10-Q 10 Nov 2020
Q1 2019 -$28,492,000 -$10,349,000 -$4,816,000 -87% 01 Jan 2019 31 Mar 2019 10-Q 10 Nov 2020
Q4 2018 -$23,676,000 -$8,563,000 01 Oct 2018 31 Dec 2018 10-K 10 Mar 2020
Q3 2018 -$5,249,000 01 Jul 2018 30 Sep 2018 10-Q 10 Dec 2019
Q2 2018 -$4,331,000 01 Apr 2018 30 Jun 2018 10-Q 10 Dec 2019
Q1 2018 -$5,533,000 01 Jan 2018 31 Mar 2018 10-Q 10 Dec 2019

Galera Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$18,957,000 +$40,125,000 +67.9% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$59,082,000 +$3,140,000 +5% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$62,222,000 +$18,312,000 +22.7% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024
2021 -$80,534,000 -$6,316,000 -8.5% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023
2020 -$74,218,000 -$22,288,000 -42.9% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022
2019 -$51,930,000 -$28,254,000 -1.2% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021
2018 -$23,676,000 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.